key: cord-0049816-rrsmcz50
authors: Medhi, Riddhiman; Srinoi, Pannaree; Ngo, Nhat; Tran, Hung-Vu; Lee, T. Randall
title: Nanoparticle-Based Strategies to Combat COVID-19
date: 2020-08-25
journal: ACS Appl Nano Mater
DOI: 10.1021/acsanm.0c01978
sha: f9a952e0ba2018ea9d1ee9987bf2ebbfe184cad8
doc_id: 49816
cord_uid: rrsmcz50

[Image: see text] Coronavirus disease 2019 (COVID-19) is the worst pandemic disease of the current millennium. This disease is caused by the highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first exhibited human-to-human transmission in December 2019 and has infected millions of people within months across 213 different countries. Its ability to be transmitted by asymptomatic carriers has put a massive strain on the currently available testing resources. Currently, there are no clinically proven therapeutic methods that clearly inhibit the effects of this virus, and COVID-19 vaccines are still in the development phase. Strategies need to be explored to expand testing capacities, to develop effective therapeutics, and to develop safe vaccines that provide lasting immunity. Nanoparticles (NPs) have been widely used in many medical applications, such as biosensing, drug delivery, imaging, and antimicrobial treatment. SARS-CoV-2 is an enveloped virus with particle-like characteristics and a diameter of 60–140 nm. Synthetic NPs can closely mimic the virus and interact strongly with its proteins due to their morphological similarities. Hence, NP-based strategies for tackling this virus have immense potential. NPs have been previously found to be effective tools against many viruses, especially against those from the Coronaviridae family. This Review outlines the role of NPs in diagnostics, therapeutics, and vaccination for the other two epidemic coronaviruses, the 2003 severe acute respiratory syndrome (SARS) virus and the 2012 Middle East respiratory syndrome (MERS) virus. We also highlight nanomaterial-based approaches to address other coronaviruses, such as human coronaviruses (HCoVs); feline coronavirus (FCoV); avian coronavirus infectious bronchitis virus (IBV); coronavirus models, such as porcine epidemic diarrhea virus (PEDV), porcine reproductive and respiratory syndrome virus (PRRSV), and transmissible gastroenteritis virus (TGEV); and other viruses that share similarities with SARS-CoV-2. This Review combines the salient principles from previous antiviral studies with recent research conducted on SARS-CoV-2 to outline NP-based strategies that can be used to combat COVID-19 and similar pandemics in the future.

A novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak of the pulmonary disease called coronavirus disease 2019 (COVID- 19) , starting in December 2019 in the city of Wuhan in China. 1−3 The primary symptoms of COVID-19 include fever, severe respiratory illness, pneumonia, and dyspnea. 1, 2 Since the initial outbreak, efficient human-to-human transmission has led to exponential growth of the virus, infecting millions of people. 1, 4 The World Health Organization (WHO) declared a Public Health Emergency of International Concern (PHEIC) on 30 January 2020 and declared the outbreak a pandemic on 11 March 2020. 3, 4 At the time of publication, SARS-CoV-2 has infected tens of millions of people across the globe, leading to more than 800,000 deaths worldwide.

The fight against a viral pandemic needs multipronged scientific approaches. The first requirement is the diagnostic detection of the virus. The development of fast and effective testing methods enables contact tracing and isolation of infected people, slowing the spread of the virus. Particularly with SARS-CoV-2, which spreads quickly through asympto-matic carriers, 5 large-scale testing is required to obtain a complete picture of viral spread. The testing methods must be accurate, suitable for mass production, inexpensive, and easy to deploy and use. Second, there is a need for therapeutic interventions that can effectively cure or reduce the effects of the virus. Therapeutics in the form of drugs and treatment strategies are essential to reduce the morbidity and mortality caused by the virus. Third, vaccines must be developed to help create antibodies, leading to eventual herd immunity. Vaccination has been able to eradicate various epidemic diseases, including smallpox, polio, and tuberculosis, in many countries. 6 However, the development of vaccines against most viral diseases has proven to be challenging. Researchers are yet to develop a vaccine for human immunodeficiency virus (HIV), which has caused over 40 million deaths to date. 7 Similarly, respiratory viral diseases (e.g., influenza) infect 3−5 million people and cause 290 000−650 000 deaths annually. 8 The 2003 SARS outbreak, which infected ∼8300 people with a mortality rate of ∼10%, eventually subsided in the summer, but there were no vaccines found at that time. 9 In 2012, the Middle East respiratory syndrome (MERS) virus affected at least 27 countries with a very high mortality rate of 35%. 10, 11 Since then, much progress has been made in the field of vaccination against coronaviruses, the principles of which apply to SARS-CoV-2 as well. SARS-CoV-2 exhibits ∼80 and 50% similarity with the genomes of SARS-CoV and MERS-CoV, respectively. 12 All coronaviruses are zoonotic viruses, and similar to the 2003 SARS-CoV, SARS-CoV-2 also has a zoonotic origin, having emerged from bats. 9 SARS-Cov-2 has approximately 96% similarity to the bat coronavirus BatCoV RaTG13. 13 SARS-CoV-2, a positive-sense single-stranded ribonucleic acid ((+)ssRNA) virus from the Coronaviridae family, is covered by an envelope with protein spikes. 12 As illustrated in Figure 1a , the four structural proteins of SARS-CoV-2 are spike surface glycoprotein (S), small envelope protein (E), matrix protein (M), and nucleocapsid protein (N). Official electron microscopy images released by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), shown in Figures 1b−e, show the morphology and structure of SARS-CoV-2. SARS-CoV-2 particles have a diameter ranging from 60 to 140 nm. 12, 14 Due to the particulate nature, morphology, and size domain of SARS-CoV-2, nanoparticle (NP)-based strategies present a powerful approach for tackling this virus. Recently, NPs have been widely used in many medical applications, such as biosensing, drug delivery, imaging, and antimicrobial treatment. 15−18 Various NPs have been shown to be effective tools for the detection and inhibition of and vaccination against coronaviruses. 19, 20 This Review describes how we can build on the NP-based strategies used against viruses from the Coronaviridae family to develop tests, therapeutics, and vaccines to fight SARS-CoV-2.

Most viral RNA detection methods are based on the reverse transcription polymerase chain reaction (RT-PCR) due to its simplicity, high sensitivity, and high specificity based on the exponential increase in RNA produced during the operation. 21, 22 Although RT-PCR methods are widely known as the standard methods for coronavirus detection, there are some limitations that need to be addressed, including low extraction efficiency, the use of time-consuming processes, and false positives caused by contamination. 23 Regarding the improvement of virus detection efficiency, due to their high surface area and ultrasmall size, NPs have been applied not only in RT-PCR methods but also other virus detection methods, such as an enzyme-linked immunosorbent assay (ELISA) and reverse transcription loop-mediated isothermal amplification (RT-LAMP). 24, 25 Various kinds of NPs have been studied in the context of virus detection, including metal NPs, carbon nanotubes, silica NPs, quantum dots (QDs), and polymeric NPs. 20, 26 Among them, metal NPs, metal nanoislands (NIs), magnetic NPs (MNPs), and QDs have been applied to coronavirus detection. Most of these diagnostic methods are Table 1 provides a summary of the NPs used in the diagnostic detection of coronaviruses.

2.1. Metal Nanoparticles and Metal Nanoislands. Most metal NP-based virus detection techniques were designed based on the unique optical and electrical properties of metal NPs. In particular, noble metal NPs, such as gold, silver, and copper, have unique optical properties called localized surface plasmon resonance (LSPR). LSPR has been utilized in biosensing applications due to the tunable light absorption and scattering wavelength in the visible region. The change in the LSPR extinction maxima of metal NPs depends on the refractive index of the surrounding media and the degree of NP aggregation, which are important factors for the use of these NPs in biological applications. 39−41 Gold NPs (AuNPs) are the most common NPs used in diagnostic detection of viruses due to their unique optical properties, stability, and biocompatible properties. 42−44 Due to the LSPR effect, the aggregation of AuNPs causes a redshift in the LSPR peak position, resulting in an obvious change in the solution color from red to blue, which can be observed with the naked eye. This phenomenon is caused by the plasmonic coupling among the neighboring NPs when the colloidal NPs aggregate. 45 The applications of AuNPs in virus detection have been reported. 42 AuNPs are also the most common metal NPs that have been used for coronavirus diagnostics. The use of AuNPs in colorimetric detection of SARS-CoV has been reported. 27 In this study, the difference in the electrostatic properties of single-and double-stranded DNA (ssDNA and dsDNA) was the foundation of the method. Specifically, ssDNA or ssRNA could interact with citrate ions on the surface of AuNPs and stabilize the particles even when salt was added into the solution, while the presence of dsDNA caused aggregation of AuNPs under the same conditions. Based on this finding, Li and Rothber designed a simple colorimetric hybridization assay to detect SARS-CoV based on the formation of dsDNA from viral ssRNA. 27 This colorimetric detection method confirmed the formation of dsDNA with a target concentration of 4.3 nM. Essentially, the results were observed within 10 min without the need for any complicated instrument. In a different approach, the formation of long dsDNA molecules from reactions of the target viral RNAs with a pair of thiolfunctionalized probes showed the ability to stabilize AuNPs under positive electrolyte conditions. 28 In the presence of the target viral RNAs of MERS-CoV, the formation of disulfide bonds between the thiol-functionalized probes, which were designed to interact with target viral RNA, caused a selfassembly process to produce long thiol-modified dsDNA molecules on the gold surface. These monolayers of the long polymer-type structures of thiol-modified dsDNA on the surface prevented the AuNPs from aggregating under positive electrolyte conditions when MgCl 2 was added into the solution (Figure 2a ). On the other hand, the thiol-modified probes, without interaction with the target molecules, stayed on the AuNP surface in individual (monomeric) or dimeric molecules, formed via a disulfide formation reaction. Due to their short chain length, both monomers and dimers of the thiol-modified probes could not prevent the aggregation of AuNPs when salt was added, as shown in Figure 2b . This colorimetric reaction led to a change in the AuNP colloidal solution color in the presence of MERS-CoV at as low as 1 pmol/μL, and the detection process took only 10 min without additional procedures.

AuNPs can be further functionalized with biomolecules to modify their surface properties. For example, colloidal AuNPs conjugated with streptavidin were used for an RT-LAMP combined with a vertical flow visualization strip (RT-LAMP-VF) assay for MERS-CoV nucleic acid detection. 29 In this study, viral RNA was amplified by RT-LAMP, followed by a labeling process to form biotin/fluorescein isothiocyanate (FITC)-labeled amplicons. These amplicons can bind to streptavidin-functionalized AuNPs to generate a complex via biotin−streptavidin interactions. This complex showed color formation when captured by an anti-FITC antibody coated on the detection strip. The formation of the complex on the strip was visible to the naked eye within 35 min. The detection limit of this technique is equivalent to 10 copies/μL of MERS-CoV RNA. Moreover, the method showed high specificity for MERS-CoV without cross-reactivity with various other CoVs, such as HCoV-HKU1, HCoV-HKU4, SARS-CoV, HCoV-229E, and HCoV-OC43. Recently, designed thiol-modified antisense oligonucleotides (ASOs) were functionalized on AuNPs for colorimetric detection of the N gene (nucleocapsid phosphoprotein) of SARS-CoV-2. 30 Specifically, in the presence of the N gene of SARS-CoV-2, the thiol-modified ASO-capped AuNPs agglomerated, which caused a change in the color of the ASO-capped AuNP colloidal solution.

Moreover, ribonuclease H (RNaseH) was added to the solution to cause visually detectable precipitation of agglomerated ASO-capped AuNPs. This method yielded the result within 10 min after the RNA isolation process. Additionally, the detection limit of this method was 0.18 ng/μL.

In addition to plasmon-based virus detection, AuNPs have been applied to electrochemical detection of coronaviruses. Layqah and Eissa reported the use of AuNPs to modify carbon array electrodes in electrochemical biosensors for both MERS-CoV and HCoV detection. 31 In this method, a viral antigen (recombinant spike protein S1 of MERS-CoV or Oc43 N of HCoV) is immobilized to the surface of AuNPs on the working electrodes. When a fixed amount of the corresponding viral antibody is added to the sample, the antibody binds to the immobilized antigen, decreasing the square wave voltammetry (SWV) reduction peak current. In the presence of virus, the change in current is different due to competition between the virus and immobilized antigen for binding to the antibody. Hence, the virus is detected based on the measured change in current in competitive immunoassays. The deposition of gold improves the electron transfer rate and increases the surface area of the electrode, resulting in high sensitivity of virus detection. 31 Specifically, this detection method was able to detect both MERS-CoV and HCoV with detection limits of 1.0 and 0.4 pg/mL, respectively. The detection process yielded results within 20 min. The method can be used for artificial nasal samples as well as to detect MERS-CoV and HCoV simultaneously.

Recently, Lee et al. developed a method for the detection of MERS-CoV based on nanoplasmonic on-chip PCR. 32 In this study, nanoplasmonic pillar arrays (NPAs) constructed from gold NIs (AuNIs) deposited on the top and side walls of glass nanopillar arrays were used to enhance the light absorption efficiency of the detection chip. Hence, ultrafast PCR thermal cycling was achieved via enhanced plasmonic photothermal heating generated via excitation of surface electrons of AuNIs by a white light-emitting diode (LED). When the LED was off, efficient heat diffusion through the NPAs allowed expeditious cooling of the PCR mixture. Consequently, this method required only 3 min and 30 s for rapid amplification of complementary DNA (cDNA) of MERS-CoV at a concentration of 0.1 ng/μL. However, the method could yield results very rapidly due to the use of gel electrophoresis for visualization of the amplicons of target viral cDNAs after the PCR. Interestingly, a faster detection technique was utilized by Wang and co-workers in a recently reported dual-function plasmonic photothermal biosensor for SARS-CoV-2 detection. 46 This biosensor combined the plasmonic photothermal (PPT) effect and LSPR biosensing technique for highly accurate detection of SARS-CoV-2 by targeting the viral RNAdependent RNA polymerase (RdRp) sequence. Two-dimensional AuNIs (5.0−5.2 nm thick) were functionalized with thiol-modified cDNA receptors of viral gene sequences (RdRp-COVID or RdRp-SARS) to create microfluidic LSPR sensor chips (Figure 3a ). Localized thermoplasmonic heating significantly improved the hybridization speed of viral gene sequence targets with their cDNA receptors immobilized on the sensor chips, enhancing the sensing performance. Importantly, this sensor can distinguish SARS-CoV and SARS-CoV-2 due to the partial mismatch between the sequences of the SARS-CoV and SARS-CoV-2 cDNA receptors, as shown in Figure 3b ,c. 46 This method exhibited high sensitivity toward SARS-CoV-2 sequences at a concentration of 0.22 pM.

Although AuNPs are the most common metal NPs used in virus detection, several studies have suggested the use of other metal NPs. Silver NPs (AgNPs) have been used in paper-based analytical devices (PADs) for MERS-CoV detection. 33 The device can also be applied in the diagnosis of other bacteria and viruses, such as Mycobacterium tuberculosis (MTB) and human papillomavirus (HPV). In this study, the authors used pyrrolidinyl peptide nucleic acid (acpcPNA)-induced aggregation of AgNPs to design a colorimetric assay. Specifically, the cationic acpcPNA probes can bind to negative citrate ions on the surface of AgNPs, inducing NP aggregation together with a change in color. On the other hand, in the presence of viral target cDNAs, acpcPNAs preferred to interact with the target cDNAs to form dsDNAs and stayed separate from AgNPs in the solution, leading to no significant color change. 33 The paper-based device exhibited high sensitivity, with detection limits of 1.53, 1.27, and 1.03 nM for MERS-CoV, MTB, and HPV, respectively.

2.2. Magnetic Nanoparticles. Magnetic NPs (MNPs) play an important role in the separation of viral RNA from solution before the diagnosis process. 47, 48 The most common MNPs that have drawn attention in the biological application field are iron oxide NPs due to their high magnetic efficiency and simple synthesis approaches. 49, 50 Regarding coronavirus detection, Gong et al. used silica-coated superparamagnetic NPs (SMNPs) in PCR-based assays to improve the selectivity of the target cDNA of SARS-CoV in the separation process. 34 Specifically, silica-coated SMNPs were conjugated with oligonucleotide probes for capturing viral target cDNAs to produce magnetic-conjugated dsDNA complexes. The magnetic-conjugated dsDNA was separated from other components by using simple magnetic separation before dehybridization to form enriched cDNAs. 34 The viral enriched cDNA was amplified through PCR followed by isolation via another magnetic separation step. The amplified viral target cDNA was detected by a sandwich hybridization assay with silica-coated fluorescent NP (SFNP)-based signaling probes. The technique can detect the target cDNA with a detection limit of 2.0 × 10 3 copies within 6 h.

Recently, MNPs have been applied to SARS-CoV-2 detection. Several studies have reported the use of iron oxide ACS Applied Nano Materials www.acsanm.org Review coated with silica for RNA extraction from patient samples. 51, 52 Furthermore, other functional groups have been reported to have strong affinity for viral RNAs. Zhou, Yu, and co-workers reported a viral RNA extraction method using poly(amino ester) with carboxyl group (PC)-coated MNPs (pcMNPs). 35 SARS-CoV-2 RNA was captured and enriched by pcMNPs to produce pcMNP−RNA complexes. Due to the magnetic property of pcMNPs, the pcMNP−RNA complexes were easily extracted from the solution by applying an external magnetic force. Interestingly, the pcMNP−RNA complexes can be immediately used in the following RT-PCR process for viral RNA amplification without the use of an elution step. The pcMNP-based extraction method exhibited high purity and high productivity within 30 min. In addition, the pcMNPs showed good binding with viral RNA, resulting in 10-copy sensitivity using the RT-PCR-based detection technique. 2.3. Quantum Dots. Due to their unique optical and electrical properties, QDs have been applied in the detection of several viruses. 53, 54 For coronavirus detection, a QDconjugated RNA aptamer specific to the SARS-CoV N protein has been reported to have high sensitivity in recognizing immobilized viral protein on designed chips. 36 The authors used commercially available QD-605 with an emission maximum at 605 nm to obtain an outstanding detection limit for the SARS-CoV N protein at 0.1 pg/mL by detecting the fluorescent emission intensity measured by confocal laser scanning microscopy. 36 The nanohybrid structures of QDs and other NPs have also been reported for coronavirus detection. Because of their extraordinary plasmonic properties, star-shaped chiroplasmonic AuNPs were combined with CdTe QDs to construct a chiral optical biosensor. 37 Two influenza virus antibodies named anti-HA and anti-NA were immobilized on the surfaces of the star-shaped gold NPs and CdTe QDs, respectively. When a recombinant protein of influenza A (H5N1) was present in the same solution containing both anti-HAconjugated AuNPs and anti-NA-conjugated QDs, AuNP− QD nanohybrids were formed through antigen−antibody interactions (immunolinking) of the recombinant protein with the two antibodies immobilized on the surfaces of the NPs and QDs. The plasmon−exciton interaction in the newly created AuNP−QD nanohybrids significantly enhanced the chiral optical response of the solution. Consequently, the viral recombinant protein was detected based on the measured circular dichroism response of the solution. In this technique, star-shaped AuNPs were chosen due to their broad plasmonic peak at 590 nm that maximizes the optical coupling and overlaps with the QD excitonic wavelength. The method showed sensitivity at 1 pg/mL for H5N1 detection and was able to detect several other viruses in blood samples, such as avian influenza A (H4N6) virus, fowl adenovirus, and coronavirus. 37 In 2018, a similar approach was used by the same research group to develop a magnetoplasmonic− fluorescent biosensor based on zirconium QDs (ZrQDs) and Fe 3 O 4 @Au core−shell magnetoplasmonic NPs (MPNPs). As shown in Figure 4 , two types of particles were functionalized with viral antibodies. The viral antibody-functionalized NPs stayed apart from each other in the solution. After the target virus was added to the system, the conjugated ZrQDs and MPNPs formed magnetoplasmonic−fluorescent nanohybrid structures via immunolinking. Hence, the detection of the target virus was based on the photoluminescence (PL) properties of the ZrQD−Fe 3 O 4 @Au MPNP nanohybrids after simple magnetic separation. The nanohybrid structures also showed a change in photoluminescence emission intensity with a change in virus concentration in the system. 38 The method can selectively detect the presence of infectious bronchitis virus (IBV) at a concentration of 79.15 EID/50 μL in blood medium. 

Much is still unknown about SARS-CoV-2, but it has been determined to be an enveloped virus with spike proteins as the main cell-infecting sites and an ssRNA as the genetic material. Many viruses investigated in NP-based antiviral research are from the coronavirus family or share a similar structure with SARS-CoV-2. NP-based therapeutic drugs can inhibit the effects of viral infection in several ways, including by blocking receptor binding and cell entry, blocking viral replication and proliferation, and directly inactivating the virus. These therapeutic strategies are discussed in this section. Table 2 lists the NPs that can be used for therapeutic strategies against coronavirus infections together with the key takeaways that can be applied for COVID-19.

3.1. Nanoparticles That Block Cell Attachment and Viral Entry. Viral infections start with the binding of viral particles to receptors on the host cells, followed by the entry of the virus into the cells. In the case of SARS-CoV-2, the spike S glycoprotein is responsible for cell binding and entry. 82, 83 As illustrated in Figure 5a , the S protein of SARS-CoV-2 can be divided into two subunits: the S1 subunit is responsible for attachment, while the S2 subunit mediates membrane fusion and entry into the cell. 82, 84 The S1 subunit consists of an Nterminal domain (NTD) and a C-domain; the S2 subunit consists of a potential fusion peptide (pFP), heptad repeats N and C (HR-N, HR-C), and a transmembrane domain (TM). The S1 protein has been shown to bind specifically to the human angiotensin-converting enzyme 2 (ACE2) receptor on the surface of human cells. 13, 82 Membrane fusion of the attached virus mostly occurs via endocytosis. 13, 83 Therefore, blocking the mechanism by which the virus binds to the ACE2 receptor or blocking viral endocytosis is a potent strategy for drug development and treatment. One of the drugs being widely considered for this purpose is chloroquine. Chloroquine has been shown to inhibit endocytosis of NPs in general; since SARS-CoV-2 is morphologically similar to NPs, chloroquine can block the endocytosis of SARS-CoV-2 virus particles as well, as illustrated in Figure 5b . 85 The proposed mechanism involves chloroquine-induced suppression of PICALM, which prevents endocytosis-mediated uptake of NPs, including SARS-CoV-2. Although chloroquine blocks NP endocytosis into the cell, the efficacy of chloroquine depends on its delivery and cellular uptake, which can be greatly aided by encapsulating the molecule inside polymeric NPs. The most commonly used NPs for encapsulating chloroquine are poly(lactic acid) (PLA) polymeric NPs. 80 In addition to facilitating drug delivery, NPs can also directly interfere with receptor binding and cell entry of viruses. Ting et al. demonstrated that ∼1.6 nm cationic carbon dots (CDs) synthesized from curcumin (CCM-CDs) can block viral entry of porcine epidemic diarrhea virus (PEDV), a coronavirus model. 76 The inhibition efficiency was over 50% at 125 μg/ mL, blocking viral entry at an early stage (see Figure 6a ). The blocking is most likely caused by electrostatic interactions between the cationic CDs and the negatively charged PEDV, which neutralizes the effective charge on the virus particles, leading to virus aggregation, as seen from the zeta potential data in Figure 6b . The CDs also suppressed the accumulation of reactive oxygen species (ROS), reducing cell apoptosis. Curcumin can also act as a reducing and capping agent in the synthesis of curcumin-modified AgNPs (cAgNPs), which have also been shown to inhibit cell entry of respiratory viruses. 60 For this purpose, smaller cAgNPs with large surface areas are seen to be more effective than larger NPs. Interestingly, smaller cAgNPs are also less cytotoxic than larger NPs. 60 The driving force behind this process is the same as that for "protein corona" formation; high surface areas of small AgNPs lead to direct interactions with the viral envelope proteins and greater inhibition. 60 Graphene QDs have also been found to be effective in interfering with cell binding of HIV, 86 while AgNPs coupled with graphene oxide (GO) sheets have been shown to be effective in blocking cell entry of feline coronavirus (FCoV) and enveloped viruses. 61 Moreover, various surface-functionalized AgNPs and AuNPs have also been shown to be effective in blocking cell entry of HIV and herpes simplex virus (HSV). 87 The advantage of AuNPs is that they are less cytotoxic than AgNPs. 88−90 In addition to virus aggregation, AuNPs can also directly interfere with the cell entry mechanism, as demonstrated by Huang et al. 59 Similar to the SARS-CoV-2 S2 subunit shown in Figure 5a , the S2 protein of MERS-CoV contains heptad repeat 1 (HR1), heptad repeat 2 (HR2), and a fusion protein (FP). As illustrated in Figure 7a , after the FP inserts into the cell membrane, HR1 and HR2 bind to form a six-helix bundle (6-HB). The 6-HB pulls together the MERS-CoV envelope and host cell membrane, promoting fusion. Huang et al. identified a peptide, named pregnancy-induced hypertension (PIH), which could mimic the conformation of HR2. Thus, this peptide can interact with HR1 to block the formation of 6-HB, inhibiting the cell fusion process. When PIH was immobilized on the surface of gold nanorods (PIH−AuNRs), a 10-fold higher inhibitory activity was observed that could completely block cell fusion at the optimized concentration (see Figure 7c ,d). The PIH−AuNRs also demonstrated excellent biocompatibility (see Figure 7b ).

In addition to AuNPs, other NPs have also been shown to be effective at blocking viral entry while maintaining low toxicity. Among synthetic NPs, porous silicon NPs (SiNPs) are especially favored due to their extreme biocompatibility. SiNPs are biodegradable, since they gradually dissolve in water to form nontoxic silicic acid. 66 Osiminka et al. showed that SiNPs were able to act as scavengers of free virus particles and prevented them from infecting host cells. Binding of SiNPs with virions is universal for different enveloped viruses, making them potential agents against SARS-CoV-2 as well. 66 Mesoporous-SiO 2 (mSiO 2 ) NPs, when functionalized with various moieties, exhibit the ability to attach themselves to enveloped viruses via hydrophobic/hydrophilic interactions. Strong bonds between the functionalized mSiO 2 NPs and the virus disturb the virus's attachment to host cell receptors and reduce viral entry into the cells. 72 Other types of biocompatible NPs known for inhibiting cellular entry of viruses include selenium NPs (SeNPs). Selenium is biocompatible, being present in several selenoproteins that are crucial for biological processes, and exhibits antiviral effects at high concentrations. 91 The antiviral activity of SeNPs can be further amplified when these NPs are combined with the antiviral drug Arbidol (ARB), effectively blocking cell entry of influenza virus and reducing cell apoptosis. Cationic chitosan, a nontoxic polysaccharide, has also shown the ability to interact with the S protein of various human coronaviruses and block their interaction with the ACE2 receptor. 92 Raghuwanshi (DCs) via the intranasal route, but these NPs have potential for use as DC-targeting drugs for blocking viral entry as well. 93 3.2. Nanoparticles That Block Viral Replication and Proliferation. For viral infection, therapeutics that inhibit the proliferation speed or infectivity of viruses are of paramount importance. These treatments will keep the virus level in the body low enough for the immune system to respond effectively and in a timely manner as the first line of defense as well as to limit the virus's capability to resist treatment via genetic mutation. Due to multiple outbreaks, respiratory diseases caused by members of the coronavirus family have received much research attention over the past decade for the development of effective therapies. Various NPs have been investigated as antiviral agents for inhibition of viral proliferation.

The infectivity of the transmissible gastroenteritis virus (TGEV), a member of the coronavirus family, is significantly diminished in the presence of AgNPs and silver nanowires (AgNWs) at concentrations below the toxic level. 62 Silver nanostructures have also been demonstrated to decrease cell apoptosis induced by viral infection. Data have suggested that Ag nanomaterials regulate p38-MAPK-p53 mitochondrial signaling cascades by inhibiting TGEV-induced expression of the Pi-p38 protein. This regulation reduces cell apoptosis induced by TGEV infection.

PEDV is a commonly studied model virus of the coronavirus family due to its high similarity to other human-infecting coronaviruses and the economic impact caused by PEDV infection. Han and co-workers reported the suppression of PEDV infection by 3 orders of magnitude via treatment with glutathione-capped Ag 2 S nanoclusters (Ag 2 S NCs). 74 The study also pointed out that the mechanisms of inhibition of viral proliferation are based on the suppression of RNA synthesis, as shown in Figure 8 . The authors further found that Ag 2 S NCs activated the generation of interferon (IFN)stimulating genes (ISGs) and cytokine expression, which further inhibited viral infection.

In addition to members of the coronavirus group, there are various viruses with structures similar to that of SARS-CoV-2 with positive-sense ssRNA genetic material, an envelope of phospholipids, and proteins. Many of these viruses have even been used as models for coronavirus research in recent years, and the efficacy of nanoparticles on these viruses could be relevant to therapy development for SARS-CoV-2. As one of the most heavily studied viruses due to multiple global pandemics in the last 100 years, influenza A viruses with their frequent genetic mutation and increasing resistance to drugs have been the target for various NP-based therapeutic research efforts. A potentially effective therapeutic target of many influenza viruses is hemagglutinin (HA), a highly conserved surface protein possessing six disulfide bonds. Haam and coworkers used porous gold NPs (PoGNPs) to target the HA protein on various influenza viruses based on strong gold−thiol interactions. 58 The results demonstrated significant inhibition of viral infectivity in cells treated with PoGNPs, and the cell viability increased to 96.8%, compared to 33.9% of nontreated cells. The viral inhibition efficacy was confirmed on the H1N1, H3N2, and H9N2 viruses to demonstrate the universal effectiveness of the approach. The biocompatibility of PoGNPs was also evaluated by the WST-1 assay, showing 95% cell viability. Alghrair ACS Applied Nano Materials www.acsanm.org Review activity than free FluPep. 94 Haag and co-workers used electron microscopy imaging to visually show that AuNPs functionalized with sialic-acid-terminated glycerol dendrons specifically targeted the viral HA protein to effectively inhibit viral proliferation. 55 Moreover, various NPs, such as oseltamivirfunctionalized AgNPs, 63 AgNP/chitosan composites, 95 zanamivir-functionalized AgNPs, 64 zanamivir-functionalized SeNPs (through the p38 and JNK signaling pathways), 67 amantadinefunctionalized SeNPs (through the ROS-mediated AKT signaling pathways), 68 ribavirin-functionalized SeNPs (via the caspase-3 apoptotic pathway), 69 oseltamivir-functionalized SeNPs, 70 PEGylated-ZnO NPs, 71 and anionic AuNPs, 56 have also been fabricated and investigated for inhibitory effects on and biocompatibility with H1N1, a current seasonal virus that caused two deadly global pandemics in 1918 and 2009.

In addition to influenza viruses, porcine reproductive and respiratory syndrome virus (PRRSV), a model virus often used for coronavirus research, has also been reported to be highly suppressed after exposure to AgNP-modified GO (GO− AgNPs) with 59.2% inhibitory efficiency. 96 GO−AgNP nanocomposite treatment also enhanced the production of IFN-α and ISGs, which can directly inhibit viral proliferation. In another study, Tong et al. reported the synthesis of glycyrrhizic-acid-based CDs (Gly-CDs) and their high inhibitory activity of up to 5 orders of viral titers through multisite inhibition of PRRSV. 77 The multisite viral inhibitory mechanisms of Gly-CDs include inhibition of viral invasion and replication, stimulation of IFN production in cells, and inhibition of viral-infection-induced ROS production, providing a promising alternative for coronavirus infection therapy as well as PRRSV infection therapy. This work also showed the remarkable ability of Gly-CDs to suppress PEDV and pseudorabies virus (PRV), suggesting a broad antiviral capability compared to previous work. 97 These results on model viruses might serve as guides for research and development on SARS-CoV-2.

The infection caused by Zika virus, a virus with a similar structure to coronaviruses and the cause of a widespread epidemic in South and North America in 2015, was suppressed by benzoxamine-monomer-derived CDs (BZM-CDs). 78 The data from a plaque uniform assay and transmission electron microscopy (TEM) showed that BZM-CDs could reduce viral infectivity via direct interaction with the viruses. The inhibitory ability of BZM-CDs was also demonstrated on Japanese encephalitis and dengue viruses, two other life-threatening viruses that also exhibit structural similarity to coronaviruses, as well as on nonenveloped viruses (e.g., adeno-associated virus (AAV), porcine parvovirus (PPV)), suggesting that the broadspectrum potential of the NPs should be further investigated for SARS-CoV-2.

Alphaviruses, a genus of RNA viruses with a structure similar to that of coronaviruses, were strongly inhibited in Vero (B) cells by cellulose nanocrystals (CNCs) modified with tyrosine sulfate mimetic ligands, while no observable cytotoxicity in human cells was detected. 79 The incorporation of tyrosine sulfate mimetic ligands on CNCs led to increased viral inhibition compared to incorporation of the control CNCs. This discovery suggests potential applications of CNCs for the treatment of HIV and HPV. In addition, studies of NP-based antiviral treatment of viruses similar to SARS-CoV-2 were also reported for AgNPs with Chikungunya virus (CHIKV) and respiratory virus (RSV), 65,98 cAgNPs with RSV, 99 and SiNPs with RSV. 66 In the coronavirus family, the outer envelope with the surface proteins is vitally important to the infection and proliferation of the virus. Various studies have reported the remarkable efficacy of NP-based inhibition of HIV by targeting the viral outer envelope using AgNPs, 100 AuNPs, 101−103 porous SiNPs, 66 and silica NPs. 72 Human-related enveloped viruses such as vesicular stomatitis virus (VSV), tacaribe virus, PRV, and HSV have also been shown to be significantly inhibited by silica NPs, 72 AgNPs, 104 CDs, 97 3.3. Nanoparticles for Viral Inactivation and Viricidal Treatment. Instead of inhibiting the cell−virion interaction, genetic material replication, or release of newly formed virions, another strategy to halt viral infection is inactivation or destruction of the virus itself. In an elegant study led by Stellacci, AuNPs coated with 3-mercaptoethylsulfonate (MES) showed viral infection inhibition at a concentration corresponding to the EC 90 , but the viral infectivity was fully recovered upon dilution. This process is called reversible viral inhibition and is similar to the effect of heparin, a common virustatic material that targets virus−cell interactions. Interestingly, the authors found that when MES was substituted by a 2:1 mixture of undecanesulfonic acid (MUS) and 1-octanethiol (OT), the MUS:OT−AuNPs could induce irreversible viral inactivation of various human-infecting viruses, ranging from HSV, VSV, RSV, and dengue virus to HPV and lentivirus. 57 The MUS ligand has a long and flexible hydrophobic backbone terminated with sulfonic acid mimicking the heparin sulfate proteoglycan (HSPG), a common and highly conserved target of viral attachment ligands, allowing effective virus−NP binding. This strong binding force (∼190 pN) led to irreversible deformation of the virus, as shown in Figure 9 .

The strong viral−MUS:OT−AuNP binding was further confirmed by electron microscopy imaging and molecular dynamics simulation. Moreover, an in vivo test in mice and an ex vivo test in human cervicovaginal histocultures also demonstrated the viral inactivation activity of the MUS:OT− AuNPs, with no cytotoxicity observed. This strategy is intrinsically broad spectrum, allowing viricidal treatment of In another study, Kong et al. showed that decoy virus receptor-functionalized nanodiscs, self-assembled discoidal phospholipid bilayers wrapped in amphipathic membrane scaffold proteins, can inactivate the H1N1 virus by selectively targeting the virion's surface proteins to cause irreversible physical damage to the envelope. 81 The antiviral activity of the viral decoy molecule sialic acid was amplified after grafting onto the nanodiscs due to the enabling of multivalent interactions with viral target proteins. The data also showed that the presence of the functionalized nanodiscs led the virus to self-disrupt its envelope with its own fusion machinery. The strength of this method is the use of biocompatible NPs and viral decoy molecules, making it a compelling method for in vivo studies. Gao and co-workers recently showed the catalytic inactivation of iron oxide (Fe 3 O 4 ) NPs targeting the viral envelopes on 12 different subtypes (H1−H12) of IAVs. 108 The ferromagnetic Fe 3 O 4 NPs with an average diameter of 200 nm were named iron oxide nanozymes (IONzymes) due to their unique enzyme-like property, catalyzing peroxidase and catalase reactions. Consequently, IONzymes could strongly induce lipid peroxidation in the viral envelope and destroy the integrity of viral surface proteins, including HA, neuraminidase, and matrix protein I, leading to inactivation of the viruses. Additionally, the authors loaded the IONzymes on facemasks and observed good protection against multiple strains of IAVs, including H1N1, H5N1, and H7N9. The biocompatibility and simple synthesis of the IONzyme nanomaterial make it attractive for effective and safe early stage antiviral therapeutics. Thus, the IONzyme nanomaterials present a potentially powerful approach against SARS-CoV-2.

In addition to the works highlighted above, other studies also reported promising inactivation and viricidal effects of different NPs on many viruses that share structural similarities with SARS-CoV-2. Among those reports are the inhibition of dengue virus by photosensitizer-carrying upconversion NPs, which can convert low-energy photons to high-energy photons; 109 inhibition of the measles virus by AuNPs synthesized by using Allium sativa (garlic extract) as a reducing agent; 110 inhibition of hepatitis C virus by AuNP-based nanozymes; 111 inhibition of HSV by poly(hexamethylene biguanide) (PHMBG) or aziridine-terminated polyethylenimine-functionalized superparamagnetic iron oxide@silica core−shell NPs; 73 inhibition of IAVs by AgNP-decorated silica particles; 112 inhibition of H1N1 virus by didodecyldimethylammonium bromide-coated silica NPs, 113 HIV by AgNPs; 114 peptide triazole Env inhibitor-conjugated AuNPs; 103 and T-cell-mimicking NPs based on poly(DLlactide-coglycolide) NP cores. 115 3.4. Nanoparticles Combining Multiple Approaches for Treatment. In addition to NPs that employ one of the three methods mentioned above to treat viral infection, various works have also shown NPs that can attack viruses via a combination of approaches. Nanoparticles that can inhibit the viruses via multiple mechanisms offer more effective opportunities for reducing viral infection through synergetic effects. Recently, Szunerits and co-workers modified carbon QDs (CQDs) of different sizes in the range of 4.5−8 nm with various functional groups, including NH 2 , COO − , N 3 , triazole, R-B(OH) 2 , and PEG, for human coronavirus (HCoV) therapy. 75 Biocompatible QCDs functionalized with triazole, boronic acid, and amino groups showed significant inhibition of HCoV infection in a concentration-correlated manner. Mechanistic studies by the authors suggested that the particles not only interfere with the replication of HCoV but also inhibit the interaction of the surface S protein with the host cell and therefore interrupt the cell fusion of HCoV as shown in Figure  10 . Rather than interacting with viral proteins, these CDs interfere with the cellular mechanism for S protein attachment and viral uptake. This work demonstrated highly promising antiviral agents based on biocompatible NPs, which should be further investigated for their activity against SARS-CoV-2, which is also an HCoV with the S protein as the main cellinfecting site. PRRSV, a model virus for coronavirus studies, has been shown to be directly inactivated and entry-blocked by glutathione-stabilized fluorescent gold nanoclusters (AuNCs). 116 Immunofluorescence assay, Western blot assay, plaque assay, and RT-qPCR assay data indicated that viral proliferation and protein expression were inhibited by AuNCs. The functionalized AuNCs in this study showed low biocompatibility and therefore may not be suitable for in vivo application. However, the coupling of AuNCs with other suitable biocompatible virus-targeting agents could lead to effective virus inactivation. 

The most effective way to fight a viral epidemic is through vaccination. The goal of vaccination is to initiate a strong immune response that leads to the development of lasting and protective immunity against the targeted pathogen. The components of the immune system can be broadly classified into two categories: innate (nonspecific) and adaptive (specific) immune systems. 117, 118 The innate immune system comprises natural killer (NK) cells, DCs, macrophages, monocytes, and innate lymphoid cells. NK cells eliminate infected cells; macrophages secrete cytokines and chemokines that induce inflammation for local defense or to facilitate tissue repair; DCs act as sentinels, carrying pathogens to adaptive immune cells; monocytes replenish macrophages and DCs; and innate lymphoid cells integrate and amplify cytokines. The Table 3 lists the NPs that can be used to trigger innate and adaptive immune responses against coronavirus infections. The most common NP-based vaccines are virus-like particles (VLPs) comprised of viral proteins, while NPs have also been used as vehicles for targeted RNA delivery to components of the innate immune system. The various NP-based vaccine designs are discussed in detail in the following sections. 4.1. Virus-Like Particles. The goal of vaccination is to deliver antigens that activate the immune system against the virus. There are various ways to generate effective vaccines. Currently, most vaccines are based on whole viruses, either live attenuated viruses or inactivated viruses. 128 However, live vaccines are unstable and difficult to deliver, and the potential for genetic reversion to a more virulent form is always a concern. On the other hand, inactivated vaccines induce a weaker immune response. In both cases, ensuring complete inactivation, the absence of any further infection, and full compliance with safety standards takes 12−18 months. This timeline is far from ideal when fighting extremely virulent diseases such as COVID-19. The alternative is to design subunit vaccines that can prime immune responses via delivery of a subset of the viral proteins. Since these vaccines have no potential for replication, subunit vaccines offer a much safer approach and can often be approved faster. Such vaccines can be enabled by using VLPs, which are protein-based NPs containing viral envelope proteins without the accompanying genetic material. Due to their particulate nature, VLPs can mimic whole viruses and are much more stable than soluble antigens. Several VLP vaccines have been licensed for clinical use against various pathogens, such as hepatitis B virus (HBV), HPV, Norwalk virus, HSV, and malaria. Early VLP designs possessed limited immunogenicity due to the absence of S epitopes on the surface of the VLPs. 129 Incorporating S epitopes in later designs yielded more immunogenic VLPs.

Coleman et al. recently developed MERS-CoV spike (S) protein NPs that can protect mice from MERS-CoV infection. 123 The spike (S) protein, primarily responsible for receptor binding and cell entry, also induces neutralizing antibodies, making the S protein an ideal target for the anti-MERS vaccine. This vaccine also stops MERS-CoV replication in the lungs. In a related study, the same research group used full-length MERS-CoV and SARS-CoV S proteins to generate ∼25 nm diameter VLPs consisting of multiple S protein molecules. 9 Inoculation with these VLPs leads to the generation of neutralizing antibodies in mice. In both of these studies, neutralizing antibody levels were significantly boosted when the VLPs were used with alum and Matrix M1 adjuvants (15-fold with alum and 68-fold with Matrix M1), as seen in Figure 11a . 9, 123 Alum is an aluminum salt that acts as a mild irritant, stimulating inflammasome responses, while Matrix M1 is a saponin-based adjuvant manufactured by Novavax, AB. 9 Novavax is currently developing COVID-19 vaccines using VLPs with full-length glycoproteins adjuvanted with Matrix M1. 118, 123, 130 Jung et al. also used MERS-CoV spike protein NPs with alum to induce specific IgG antibodies in mice. 11 The spike protein NPs had a diameter of 35 nm, which increased to 80 nm when the NPs were formulated with alum. When used in conjunction with a recombinant adenovirus serotype 5 encoding the MERS-CoV spike gene (Ad5/MERS), Th1/Th2 activation was balanced, generating a longer-lasting antibody response. Figure 11b shows the effectivity of this VLP in MERS-infected mice. The selfassembly of MERS-CoV protein NPs can be further assisted by a ferritin template to ensure the display of target antigens on the surface. 131 Since the spike S protein of coronaviruses is the most important antigenic determinant for inducing neutralizing antibodies, repetitive display of these S protein epitopes on the surface of the VLPs stimulates a stronger immune response. Pimental et al. observed that even using a smaller segment of the S protein may be sufficient if the epitopes are concentrated on the surface. 124 Using template-based synthesis with coiled-coil proteins, the C-terminal heptad repeat region (HRC), and a small segment of the S protein, they generated VLPs (see Figure 11c ) that were able to stimulate anti-SARS antibodies even in the absence of an adjuvant, attributed largely to its nanometer size, repetitive display of the epitope, and good mimicry of the epitope's natural configuration. Similar results were also observed by Sharma et al. when they incorporated multiple copies of the HA protein on the surface of the VLPs; HA is a surface-exposed glycoprotein and is the most highly immunogenic target for IAV. Immunization of IAV-infected mice with HA-conjugated surface VLPs provided full protection from morbidity and mortality without the need for additional adjuvants. 8 Thus, we observed that VLPs based on the spike S protein of MERS-CoV and SARS-CoV were effective in stimulating a strong antibody response. The antibody response is enhanced in the presence of adjuvants or by concentrating multiple repeating units of the S protein on the surface of the VLPs.

ACS Applied Nano Materials www.acsanm.org Review Wang et al. designed novel chimeric VLPs using a canine parvovirus structural protein with the receptor-binding domain (RBD) of MERS-CoV. 125 Parvovirus-like particles are very stable, highly immunogenic, and do not cause disease in humans, making them a safe expression platform, while the RBD unit of MERS-CoV is a major antigenic determinant for antibody induction. RBD-specific humoral antibody responses were detected in mice treated with these VLPs 2 weeks after injection and were significantly enhanced in the presence of a polyriboinosinic acid [poly(I:C)] adjuvant. The VLPs produced a Th1-based response with significant IL-2 secretion, while the VLPs with poly(I:C) adjuvant produced mixed Th1 and Th2 responses, producing IFN-γ, IL-2, and IL-4 responses. The IgG antibody titer in mice treated with VLPs along with the adjuvant showed a 320-fold increase in mouse sera. The poly(I:C) adjuvant is able to activate a relatively high number of DCs in lymph nodes to generate a robust immune response. Cross-virus VLP design was also studied by Carter et al. 132 SARS-CoV polyprotein 1a (pp1a) self-assembled into VLPs that were found to be effective against idiopathic pulmonary fibrosis (IPF) caused by Herpesvirus saimiri (HVS). These two studies show that VLPs developed using subunits from one virus can serve as effective vaccines against other viruses as well. ARTES Biotechnology has utilized duck hepatitis B small surface antigen to design an enveloped VLP (eVLP) technology called METAVAX to deliver SARS-CoV-2 spike S protein-loaded vaccines. ARTES Biotechnology is also utilizing another vaccine technology using capsid VLPs (cVLPs), called SplitCore, to develop vaccines using SARS-CoV-2 S antigens. Ufovax, a spin-off vaccine company from Scripps Research, is also developing COVID-19 vaccines using self-assembling protein VLPs (1c-SApNP technology). Similar COVID-19 vaccines with VLPs are also being developed by Medicago (plant-derived VLPs), iBio, Inc. (SARS-CoV-2 VLPs), ExpreS2ion (protein subunit VLPs), GeoVax Laboratories (GV-MVA-VLP), BIKEN (protein subunit VLPs), Saiba GmbH (RBD-based VLPs), Imophoron Ltd. (ADDomer), LakePharma (protein subunit NPs), and VBI Vaccine Inc. (enveloped VLPs); most of these vaccines are already in either in the preclinical or clinical trial phase. 130 4.2. Chitosan, Protein Cage, and Polymer Nanoparticles for Targeted Vaccine Delivery. NPs have been widely explored for drug delivery applications due to their favorable size, photothermal and magnetic properties, controlled release, and easy functionalization, enabling targeted attachment to specific cell types. 133−137 Many researchers have also attempted to utilize these attributes for targeted vaccine delivery to cellular components of the immune system. DCs are special sentinel cells, a type of APCs. Various strategies employed for selective targeting of DCs have shown great potential in the design of low-dose vaccines. 138 Raghuwanshi et al. designed a vaccine targeting DCs using chitosan NPs as delivery vehicles. 93 Chitosan is a natural polysaccharide that binds strongly to nucleic acids due to its cationic charge, 139, 140 which makes these NPs ideal nucleic acid delivery vehicles, further aided by their excellent biocompatible, biodegradable, and nontoxic nature. Raghuwanshi et al. formulated NPs by loading negatively charged plasmid DNA encoding nucleocapsid (N) protein as a SARS-CoV vaccine antigen on cationic biotinylated chitosan NPs. Compared to the S protein, the N protein is more highly conserved in coronaviruses, which offers the ability to design broad-spectrum effectiveness across various mutating strands of the Coronaviridae family. For ACS Applied Nano Materials www.acsanm.org Review example, compared to the S gene in SARS-CoV-2, which is divergent (>25%) when compared to all other previously described SARS-related coronaviruses, the other three structural proteins are more highly conserved than the spike protein and are necessary for general coronavirus function. 12 Additionally, similar to SARS-CoV and MERS-CoV, SARS-CoV-2 also primarily attacks the respiratory system, causing acute respiratory distress and pulmonary damage. 10, 12, 141, 142 For this reason, Raghuwanshi et al. specifically administered the N protein-loaded chitosan NP vaccine intranasally, targeting the mucosal pathway, mimicking the route of an actual viral infection, 93 which induces both humoral and cellular immune responses. Naked DNA is ineffective in crossing mucosal barriers and is rapidly degraded by nucleases, while chitosan NPs transiently open the tight junctions to allow increased transport across the nasal mucosa. As a result, significant N protein-specific IgG, IgG1, IgG2a, and IgG2b antibodies, as well as IFN-γ and Th1 cytokine responses, were stimulated. Compared to systemic vaccination, mucosal vaccination is often more effective against mucosal pathogens due to the ability of these pathogens to induce secretory nasal antibodies. 93, 126 Wiley et al. designed a safe broad-spectrum vaccine against multiple coronaviruses using a protein cage NP (PCN) that targets mucosal cells. 126 The PCN does not contain any antigen-specific proteins but is derived from a small heat shock protein (sHsp 16.5) instead, which causes the formation of inducible bronchus-associated lymphoid tissue (iBALT). The iBALT strategy provides an alternative approach for broad-spectrum viral protection in the lungs. The PCNinduced iBALT structures contain B cells, CD4 + T cells, DCs, and CD8 + T cells. CD4 + and CD8 + T cells accumulated rapidly in the lungs of PCN-treated mice. These iBALT responses protected the mice from lethal doses of various respiratory viruses (H1N1, SARS, RSV). Protection against SARS-CoV was already apparent within 3 days after infection, implying that innate mechanisms are also modulated by this PCN treatment (see Figure 12b ). Despite the strong antiviral response, no histological damage was observed in the alveolar architecture of the lungs, and eosinophilic influx into the lungs was reduced. Thus, this PCN vaccination targeting iBALT microstructures can nonspecifically enhance immune protection against a diversity of respiratory viruses and in the absence of pulmonary inflammation, thus effectively protecting the host (see Figure 12c ).

For cell-specific targeted vaccination strategies, NPs with dimensions of ∼100 nm have been generally found to be good for cellular uptake by DCs via phagocytosis, since they resemble the natural targets for DCs, such as viruses or bacteria. 118 Several studies have found that the submicron size is optimal for mucosal cell uptake and that NPs less than 200 nm in size are more readily transported by draining lymph nodes. 140 NPs with sizes of 20−200 nm have long circulation times and become enriched in lymph nodes, leading to enhanced lymphatic transport, allowing direct access to lymphoid-node-resistant DCs. 118 This feature enhances antigen uptake and presentation to B cells, enhancing the humoral response, or to T cells, allowing immunomodulation. 118 Cationic NPs have been widely used to deliver small interfering RNA (siRNA) to the lungs for the treatment of various respiratory diseases over the years via intranasal and intratracheal routes. 143 To combat a rapidly spreading virus such as SARS-CoV-2, mRNA (mRNA)-based vaccines are promising candidates, since they can be scaled rapidly. Cationic lipid NPs encapsulating mRNA are being widely explored for the development of COVID-19 vaccines. 144 Lipid NPs (LNPs) can deliver mRNA to the cytoplasm, where the mRNA can undergo direct translation to the target protein; this process can then trigger APCs and activation of B cells and T cells. 144 A vaccine developed by Moderna in collaboration with NIAID, containing mRNA encapsulated inside lipid NPs, is currently in phase-2 human clinical trials. 130, 145 Moderna's previous MERS and SARS vaccines developed using a similar design had demonstrated 90% reduction in viral load. 145 In addition, vaccines by BioNTech/Pfizer/Fosun Pharma (LNP− mRNA) are also in phase-1/2 trials, while Translate Bio/Sanofi Pasteur (LNP−mRNA), CanSino Biologics/Precision Nano-Systems (LNP−mRNA), Daiichi-Sankyo (LNP−mRNA), BioPharma (mRNA VLPs), and RNACure Biopharma (LNPencapsulated mRNA VLPs) are also developing lipid NPencapsulated mRNA vaccines, currently in preclinical trials. 130 Another type of NP used to deliver genetic materials to the lungs via nasal instillation is calcium phosphate (CaP). 146 Since CaP is a naturally occurring substance in mammalian hard tissues, it is a safe and biocompatible biomedical carrier. Additionally, acting as a mucosal adjuvant, CaP can initiate an immune response stronger than that induced by aluminum salts and for longer durations. 129 CaP is often encapsulated with polymers such as poly(lactic-coglycolic acid) (PLGA) and polyethylenimine (PEI), to increase cellular uptake. 146 PEI is known for facilitating targeted delivery and stimulating immune responses in alveolar cells and macrophages, along with other polymeric derivatives of PLGA, such as poly(DL- Figure 13 ). 127 Due to the acidsensitive PLGA hydrolysis, the NPs readily release the adjuvant upon cellular uptake, as seen in Figure 13 . Localized at the endoplasmic reticulum, STING is a potent inducer of proinflammatory cytokines such as IFN-β, TNF-α, and IL-6. When combined with the MERS-CoV spike protein, the STING-PLGA NP size increases to ∼148 nm, which leads to a virus-like distribution of the NPs, synchronizing lymph node delivery of surface-coated antigens and interiorly loaded adjuvant. Further conjugation with the state-of-the-art influenza adjuvant MF59 (Addavax) induced significantly higher levels of antigen-specific antibodies due to balanced Th1 and Th2 responses. Higher antibody titers and longerlasting responses due to a balanced Th1/Th2 response were also observed by Jung et al., as described previosuly. 11 The polymer-based NPs with STING and MF59 adjuvants were superior in their ability to mount humoral responses compared to free STING agonists or MF59 alone. This study strongly demonstrated the advantages of hollow polymeric NPs as vaccine delivery vehicles due to their biocompatibility, size consistency, colloidal stability, tunable adjuvant loading, pHresponsive release, and antigen functionalizability. 4.3. Quantum Dots and Gold Nanoparticles. QDs, with sizes much smaller than the aforementioned NPs, have also been utilized for designing vaccines against coronaviruses. Positively charged carbon QDs with dimensions of ∼1.6 nm, made from curcumin, were studied as vaccines against PEDV, a model coronavirus. 76 Although these CDs primarily blocked viral cell entry, they also induced the production of ISGs that suppress viral replication and budding. Ag 2 S nanocrystals (NCs), another type of QD, were also found to positively regulate ISGs and the expression of proinflammatory cytokines. 74 However, among inorganic NPs, the most commonly employed NPs in vaccine design are AuNPs. Sekimukai et al. discovered that AuNPs can act as both an antigen carrier for the SARS-CoV spike S protein and an adjuvant. 121 AuNPs bind to the S protein via electrostatic interactions, forming a protein corona around the AuNPs. Mice immunized with these NPs showed Th1 and Th2 responses; however, these responses were accompanied by allergic inflammation and eosinophilic infiltration. Chen et al. utilized AuNPs to formulate synthetic VLPs (sVLPs) by incubating 100 nm AuNPs in a solution containing the spike S protein of avian coronavirus infectious bronchitis virus (IBV), as shown in Figure 14 . 122 Following removal of free protein, antigen-loaded AuNPs were recovered that resembled natural viral proteins, as seen in Figure 14 . Protein corona formation increased the NP size to 139 nm, which remained stable over a 7 day period, with each particle retaining approximately 200− 250 spike proteins. Compared to inoculation with free proteins, vaccination with these synthetic VLPs showed enhanced lymphatic antigen delivery (6-fold), stronger antibody titers, increased T cell response, and reduced symptoms (see Figure 14) . Thus, there are multiple advantages to using AuNPs as next-generation vaccine delivery agents. (1) Inorganic NPs such as AuNPs have high surface energy, leading to spontaneous protein corona formation. 121 As a result, a smaller amount of antigen is required than VLPs to make antigen-exposing NPs of sizes comparable to those of coronaviruses, generating CD4 + T cell and B cell responses. 147 Easy functionalization of AuNPs allows the loading of various other nucleic acids as well. (2) With the NP acting as an adjuvant itself, additional adjuvants are not necessary. 121, 147 (3) AuNPs used as antigen carriers also stimulate phagocytic activity of lymphoid cells, stimulate APCs, and induce the release of inflammatory mediators. 147 Localization of AuNPs to ACS Applied Nano Materials www.acsanm.org Review lymphatic tissues and cells is notable, as it mimics what occurs during a natural infection. AuNPs primarily enter cells via phagocytosis, stimulating macrophages, DCs, and lymphocytes. 147 Phagocytosis of NPs is determined by their size and shape. 147 AuNPs with dimensions of 40−100 nm are ideal for phagocytosis, while shape dependence follows the order ellipsoid > spheres > rods > cubes, although in some cases, rods are internalized better than spheres. 118, 148, 149 However, larger spherical virus-like AuNPs generate the strongest antibody responses. (4) AuNPs have good stability and low cytotoxicity. 88, 148 5. SUMMARY AND PERSPECTIVES 5.1. Nanoparticles for Diagnostics. NPs have been applied to various kinds of virus detection methods. Metal NPs and QDs with unique optical properties have the advantages of enhanced sensitivity for optical biosensing. Meanwhile, MNPs are mainly applied to the virus extraction process due to their magnetic properties. Additionally, the nanohybrid structures combine the advantages of each type of NP to improve the efficiency of virus detection. Recently, NP-based virus detection has been reported as a promising technique to detect the recently discovered SARS-CoV-2, the virus that causes COVID-19. With further research and development, NPs will undoubtedly play an important role in improving not only coronavirus detection efficiency but also other biological pathogen diagnoses. 5.2. Nanoparticles for Therapeutics. Overall, the studies covered in this section show that various NPs can be used to design drugs aimed at disrupting the attachment of SARS-CoV-2 to the ACE2 receptor and blocking the cell entry process while themselves remaining largely nontoxic toward the host cells. Effective antiviral therapies, especially in the early stage of infection, are vitally important to halt viral proliferation long enough for the immune system to respond to the virus and limit cellular damage inflicted by viral invasion as well as to minimize genetic mutations caused by the high replication frequency of the virus, which might lead to therapeutic resistance. NPs with various structures, compositions, and conjugations have been fabricated and evaluated in multiple conditions as highly effective enhancements or alternatives to many existing antiviral therapeutics associated with increasing drug resistance. The antiviral performance, stability, and biocompatibility of these NPs have been rigorously investigated on different human-infecting viruses ranging from members of the coronavirus family to other viruses with close structural similarity to SARS-CoV-2 itself. Using novel antiviral approaches with flexible combinations, many NPs have also been demonstrated to be effective against a broad spectrum of viruses with minimal cytotoxicity, suggesting that these NPs are good research candidates for NP-based antiviral therapies to fight the COVID-19 pandemic.

5.3. Nanoparticles as Immunogenic Agents for Vaccines. Overall, the studies covered in this section offer valuable insight needed for the development of vaccines for COVID-19. The following four conclusions can be drawn: (1) Self-assembled VLPs, template-based and supported VLPs, and synthetic VLPs can all be systematically formulated in sizes and shapes that mimic those of original coronaviruses. These features help induce strong immune responses while avoiding exposure to the virulent genetic components of the virus itself.

(2) Repetitive decoration of antigens on the surface of NP vaccines can enhance immune responses, even when using smaller subsets of the proteins; this effect can be further enhanced by matching the natural configuration of the epitopes. Vaccine development has typically exploited coronavirus S protein epitopes, but N protein epitopes can also be utilized to design broad-spectrum vaccines. (3) NPs offer the opportunity to combine antigen delivery abilities with adjuvant properties. (4) Vaccines targeted specifically toward mucosal cells, DCs, and lymph nodes generate stronger localized immune responses against respiratory viruses such as SARS-CoV-2. Nanosized particles (40−200 nm) are especially suitable for targeted delivery to mucosal and alveolar structures, mimicking natural infection routes and inducing direct immune responses in the worst affected tissues.

Thus, NPs are expected to play a major role in the fight against COVID-19. The optical and magnetic properties of various NPs can be utilized for building diagnostic test kits. The stark morphological and physicochemical similarities of SARS-CoV-2 with synthetic NPs also make NPs a powerful tool for intervention. NPs can be systematically functionalized with various proteins, polymers, and functional groups to perform specific inhibitory functions while also acting as excellent delivery vehicles. NPs offer possibilities for fast and safe vaccine development using subunit proteins instead of whole viruses. Additionally, NPs can also be utilized to make broad-spectrum respiratory drugs and vaccines that can protect us from seasonal viruses and prepare us for future pandemics as well.

A Familial Cluster of Pneumonia Associated with the 2019 Novel Coronavirus Indicating Person-to-Person Transmission: A Study of a Family Cluster

Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan

Cryo-EM Structure of the 2019-Ncov Spike in the Prefusion Conformation

Main Protease Provides a Basis for Design of Improved α-Ketoamide Inhibitors

Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19

at Last! The Progress of New Disease Eradication Campaigns for Guinea Worm Disease and Polio, and the Prospect of Tackling Other Diseases

Clinical Challenges in HIV/ AIDS: Hints for Advancing Prevention and Patient Management Strategies

A Self-Adjuvanted, Modular, Antigenic VLP for Rapid Response to Influenza Virus Variability

Purified Coronavirus Spike Protein Nanoparticles Induce Coronavirus Neutralizing Antibodies in Mice

Middle East Respiratory Syndrome Vaccine Candidates: Cautious Optimism

Heterologous Prime−Boost Vaccination with Adenoviral Vector and Protein Nanoparticles Induces Both Th1 and Th2 Responses against Middle East Respiratory Syndrome Coronavirus

Diagnosing Covid-19: The Disease and Tools for Detection

Structural Basis for the Recognition of SARS-CoV-2 by Full-Length Human ACE2

Nano Research for Covid-19

Nanoparticle-Based Immunochemical Biosensors and Assays: Recent Advances and Challenges

Nano Based Drug Delivery Systems: Recent Developments and Future Prospects

Applications of Nanoparticles in Biomedical Imaging

Recent Developments in Antibacterial Therapy: Focus on Stimuli-Responsive Drug-Delivery Systems and Therapeutic Nanoparticles

An Overview of Functional Nanoparticles as Novel Emerging Antiviral Therapeutic Agents

Metal Nanoparticles for Virus Detection

Detection of 2019 Novel Coronavirus

Recent Advances and Perspectives of Nucleic Acid Detection for Coronavirus

Real-Time Reverse Transcription-Polymerase Chain Reaction Assay for SARS-Associated Coronavirus

Progress in the Study of Virus Detection Methods: The Possibility of Alternative Methods to Validate Virus Inactivation

Characterization of Novel Monoclonal Antibodies against the MERS-Coronavirus Spike Protein and Their Application in Species-Independent Antibody Detection by Competitive Elisa

Nanomaterial-Based Biosensors for Detection of Pathogenic Virus

Colorimetric Detection of DNA Sequences Based on Electrostatic Interactions with Unmodified Gold Nanoparticles

Development of Label-Free Colorimetric Assay for MERS-CoV Using Gold Nanoparticles

A Rapid and Specific Assay for the Detection of MERS-CoV

Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene Targeted Antisense Oligonucleotide Capped Plasmonic Nanoparticles

An Electrochemical Immunosensor for the Corona Virus Associated with the Middle East Respiratory Syndrome Using an Array of Gold Nanoparticle-Modified Carbon Electrodes

Nanoplasmonic on-Chip PCR for Rapid Precision Molecular Diagnostics

Multiplex Paper-Based Colorimetric DNA Sensor Using Pyrrolidinyl Peptide Nucleic Acid-Induced AgNPs Aggregation for Detecting MERS-CoV, MTB, and HPV Oligonucleotides

Combination of Functionalized Nanoparticles and Polymerase Chain Reaction-Based Method for SARS-CoV Gene Detection

A Simple Magnetic Nanoparticles-Based Viral RNA Extraction Method for Efficient Detection of SARS-CoV-2

Quantitative and Sensitive Detection of SARS Coronavirus Nucleocapsid Protein Using Quantum Dots-Conjugated RNA Aptamer on Chip

Self-Assembled Star-Shaped Chiroplasmonic Gold Nanoparticles for an Ultrasensitive Chiro-Immunosensor for Viruses

Chiral Zirconium Quantum Dots: A New Class of Nanocrystals for Optical Detection of

Localized Surface Plasmon Resonance: A Unique Property of Plasmonic Nanoparticles for Nucleic Acid Detection

Localized Surface Plasmon Resonance Biosensing: Current Challenges and Approaches

Bimetallic Nanoparticles: Enhanced Magnetic and Optical Properties for

Gold Nanoparticles: A Paradigm Shift in Biomedical Applications

Interparticle Coupling Effect on the Surface Plasmon Resonance of Gold Nanoparticles: From Theory to Applications

Dual-Functional Plasmonic Photothermal Biosensors for Highly Accurate Severe Acute Respiratory Syndrome Coronavirus 2 Detection

Magnetic Nanoparticles-Based Extraction and Verification of Nucleic Acids from Different Sources

Magnetic Separations in Biotechnology

Biosensing Using Magnetic Particle Detection Techniques

Sensors and Biosensors Based on Magnetic Nanoparticles

Preparation of Iron Oxide Silica Particles for Zika Viral RNA Extraction

Simultaneous Extraction of DNA and RNA from Hepatocellular Carcinoma (Hep G2) Based on Silica-Coated Magnetic Nanoparticles

A Microfluidic Device with Microbead Array for Sensitive Virus Detection and Genotyping Using Quantum Dots as Fluorescence Labels

Quantum Dot-Fluorescence In Situ Hybridisation for Ectromelia Virus Detection Based on Biotin−Streptavidin Interactions

Inhibition of Influenza Virus Infection by Multivalent Sialic-Acid-Functionalized Gold Nanoparticles

Effective Multi-Strain Inhibition of Influenza Virus by Anionic Gold Nanoparticles

Broad-Spectrum Non-Toxic Antiviral Nanoparticles with a Virucidal Inhibition Mechanism

Porous Gold Nanoparticles for Attenuating Infectivity of Influenza a Virus

Novel Gold Nanorod-Based HR1 Peptide Inhibitor for Middle East Respiratory Syndrome Coronavirus

Curcumin Modified Silver Nanoparticles for Highly Efficient Inhibition of Respiratory Syncytial Virus Infection

Antiviral Activity of Graphene−Silver Nanocomposites against Non-Enveloped and Enveloped Viruses

Silver Nanoparticle Based Codelivery of Oseltamivir to Inhibit the Activity of the H1N1 Influenza Virus through ROS-Mediated Signaling Pathways

The Inhibition of H1N1 Influenza Virus-Induced Apoptosis by Silver Nanoparticles Functionalized with Zanamivir

Antiviral and Immunomodulatory Activity of Silver Nanoparticles in Experimental RSV Infection

Porous Silicon Nanoparticles as Scavengers of Hazardous Viruses

Inhibition of H1N1 Influenza Virus by Selenium Nanoparticles Loaded with Zanamivir through P38 and Jnk Signaling Pathways

Inhibition of H1N1 Influenza Virus-Induced Apoptosis by Functionalized Selenium Nanoparticles with Amantadine through ROS-Mediated AKT Signaling Pathways

Restriction of H1N1 Influenza Virus Infection by Selenium Nanoparticles Loaded with Ribavirin Via Resisting Caspase-3 Apoptotic Pathway

Inhibitory Activity of Selenium Nanoparticles Functionalized with Oseltamivir on H1N1 Influenza Virus

Ataei-Pirkooh, A. Inhibition of H1N1 Influenza Virus Infection by Zinc Oxide Nanoparticles: Another Emerging Application of Nanomedicine

Viral Inhibition Mechanism Mediated by Surface-Modified Silica Nanoparticles

Antiviral Properties of Polymeric Aziridine-and Biguanide-Modified Core−Shell Magnetic Nanoparticles

Glutathione-Capped Ag 2 S Nanoclusters Inhibit Coronavirus Proliferation through Blockage of Viral RNA Synthesis and Budding

Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus

Multisite Inhibitors for Enteric Coronavirus: Antiviral Cationic Carbon Dots Based on Curcumin

Glycyrrhizic-Acid-Based Carbon Dots with High Antiviral Activity by Multisite Inhibition Mechanisms

Benzoxazine Monomer Derived Carbon Dots as a Broad-Spectrum Agent to Block Viral Infectivity

Synthesis of Cellulose Nanocrystals Carrying Tyrosine Sulfate Mimetic Ligands and Inhibition of Alphavirus Infection

A. A. Improving Encapsulation of Hydrophilic Chloroquine Diphosphate into Biodegradable Nanoparticles: A Promising Approach against Herpes Virus Simplex-1 Infection

Virucidal Nano-Perforator of Viral Membrane Trapping Viral Rnas in the Endosome

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Characterization of Spike Glycoprotein of SARS-CoV-2 on Virus Entry and Its Immune Cross-Reactivity with SARS-CoV

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Insights from Nanomedicine into Chloroquine Efficacy against Covid-19

Graphene Quantum Dots Based Systems as HIV Inhibitors

Silver Nanoparticles as Potential Antiviral Agents

Cytotoxicity and Immunological Response of Gold and Silver Nanoparticles of Different Sizes

A Review of the In Vivo and In Vitro Toxicity of Silver and Gold Particulates: Particle Attributes and Biological Mechanisms Responsible for the Observed Toxicity

Toxicity Assessments of Multisized Gold and Silver Nanoparticles in Zebrafish Embryos

Inhibition of H1N1 Influenza Virus-Induced Apoptosis by Selenium Nanoparticles Functionalized with Arbidol through ROS-Mediated Signaling Pathways

HTCC: Broad Range Inhibitor of Coronavirus Entry

Dendritic Cell Targeted Chitosan Nanoparticles for Nasal DNA Immunization against SARS CoV Nucleocapsid Protein

Enhanced Inhibition of Influenza Virus Infection by Peptide-Noble-Metal Nanoparticle Conjugates

Antiviral Activity of Silver Nanoparticle/Chitosan Composites against H1n1 Influenza a Virus

Antiviral Activity of Graphene Oxide−Silver Nanocomposites by Preventing Viral Entry and Activation of the Antiviral Innate Immune Response

Carbon Dots as Inhibitors of Virus by Activation of Type I Interferon Response

Green Synthesis of Silver Nanoparticles from Medicinal Plants and Evaluation of Their Antiviral Potential against Chikungunya Virus

Curcumin Modified Silver Nanoparticles for Highly Efficient Inhibition of Respiratory Syncytial Virus Infection

Interaction of Silver Nanoparticles with HIV-1

Inhibition of HIV Fusion with Multivalent Gold Nanoparticles

Gold Nanoparticles Capped with Sulfate-Ended Ligands as Anti-HIV Agents

Chaiken, I. Mechanism of Multivalent Nanoparticle Encounter with HIV-1 for Potency Enhancement of Peptide Triazole Virus Inactivation

Interaction of Silver Nanoparticles with Tacaribe Virus

Inhibition of Herpes Simplex Virus Type 1 Infection by Silver Nanoparticles Capped with Mercaptoethane Sulfonate

Antiviral Activity of Tannic Acid Modified Silver Nanoparticles: Potential to Activate Immune Response in Herpes Genitalis

Antiviral Activity of Mycosynthesized Silver Nanoparticles against Herpes Simplex Virus and Human Parainfluenza Virus Type 3

Catalytic Inactivation of Influenza Virus by Iron Oxide Nanozyme

Photodynamic Inactivation of Viruses Using Upconversion Nanoparticles

Virucidal Activity of Gold Nanoparticles Synthesized by Green Chemistry Using Garlic Extract

Nanoparticle-Based Artificial RNA Silencing Machinery for Antiviral Therapy

Inactivation of Influenza a Virus Via Exposure to Silver Nanoparticle-Decorated Silica Hybrid Composites

Nanoparticles and Surfaces Presenting Antifungal, Antibacterial and Antiviral Properties

Mode of Antiviral Action of Silver Nanoparticles against HIV-1

T-Cell-Mimicking Nanoparticles Can Neutralize HIV Infectivity

Glutathione-Stabilized Fluorescent Gold Nanoclusters Vary in Their Influences on the Proliferation of Pseudorabies Virus and Porcine Reproductive and Respiratory Syndrome Virus

Nanoparticle Formulated Vaccines: Opportunities and Challenges

Cytokines and Immunity to Viral Infections

Antiviral Activity of Tumor Necrosis Factor (TNF) Is Mediated Via P55 and P75 TNF Receptors

Gold Nanoparticle-Adjuvanted S Protein Induces a Strong Antigen-Specific IgG Response against Severe Acute Respiratory Syndrome-Related Coronavirus Infection, but Fails to Induce Protective Antibodies and Limit Eosinophilic Infiltration in Lungs

Synthetic Virus-Like Particles Prepared Via Protein Corona Formation Enable Effective Vaccination in an Avian Model of Coronavirus Infection

MERS-CoV Spike Nanoparticles Protect Mice from MERS-CoV Infection

Peptide Nanoparticles as Novel Immunogens: Design and Analysis of a Prototypic Severe Acute Respiratory Syndrome Vaccine

Novel Chimeric Virus-Like Particles Vaccine Displaying MERS-CoV Receptor-Binding Domain Induce Specific Humoral and Cellular Immune Response in Mice

Inducible Bronchus-Associated Lymphoid Tissue Elicited by a Protein Cage Nanoparticle Enhances Protection in Mice against Diverse Respiratory Viruses

Viromimetic Sting Agonist-Loaded Hollow Polymeric Nanoparticles for Safe and Effective Vaccination against Middle East Respiratory Syndrome Coronavirus

Viral Nanoparticles and Virus-Like Particles: Platforms for Contemporary Vaccine Design

Nanotechnology in Vaccine Delivery

Draft Landscape of COVID-19 Candidate Vaccines

A Unique Protein Self-Assembling Nanoparticle with Significant Advantages in Vaccine Development and Production

The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis

Nanoparticle-Based Targeted Drug Delivery

Nanoparticles for Drug Delivery to the Lungs

Magnetic Nanoparticles for Drug Delivery

Porous Silver-Coated pNIPAM-Co-AAc Hydrogel Nanocapsules

Dendritic-Cell Immunotherapy: From Ex Vivo Loading to In Vivo Targeting

Biopolymeric Nano/Microspheres for Selective and Reversible Adsorption of Coronaviruses

Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives

Pathology and Pathogenesis of Severe Acute Respiratory Syndrome

Nanoscale Particles for Lung Delivery of siRNA

An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development

Research and Development on Therapeutic Agents and Vaccines for Covid-19 and Related Human Coronavirus Diseases

Local Delivery of siRNA-Loaded Calcium Phosphate Nanoparticles Abates Pulmonary Inflammation

Immunological Properties of Gold Nanoparticles

AuNPs): A New Frontier in Vaccine Delivery

Gold Nanoparticles as a Vaccine Platform: Influence of Size and Shape on Immunological Responses In Vitro and In Vivo

The authors declare no competing financial interest.

We thank the Air Force Office of Scientific Research (AFOSR FA9550-18-1-0094), the Robert A. Welch Foundation (E-1320), the Texas Center for Superconductivity, and the University of Houston Advanced Manufacturing Institute for generously supporting this research.